Drug design, development and therapy · 2026
Therapeutic Alternatives to Recombinant Biologics: Mechanistic Framework, Clinical Evidence, and Selection Guidance.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Niazi Sarfaraz K
Аннотация
INTRODUCTION: Recombinant biologics have transformed modern medicine but face persistent limitations, including high costs ($24,000-500,000 annually), injection burden, immunogenicity, manufacturing complexity ($200-500M in facility investments), and global barriers that limit access for billions worldwide. These challenges drive an urgent need for therapeutic alternatives.
AREAS COVERED: We evaluate six primary alternative modalities across FDA- and EMA-approved agents and pipeline candidates (2014-2025): oral small molecules targeting intracellular pathways, RNA therapeutics using gene silencing, CD36-mediated protein degraders (PROTACs), pharmacological chaperones, substrate-reduction therapies, and oral peptide formulations []. Clinical evidence from multiple FDA approvals demonstrates successful substitution: fitusiran achieves an 84-91% reduction in bleeding, iptacopan provides 61% transfusion independence, and deucravacitinib achieves 58.7% PASI-75 response. We identify four mechanistic principles-pathway convergence targeting, functional mimicry, allosteric modulation, and tissue-selective approaches-that can guide recombinant drug substitutions. Manufacturing analysis reveals potential for substantial cost advantages, although actual patient access requires policy intervention beyond market forces.
EXPERT OPINION: Therapeutic alternatives represent a fundamental evolution in pharmaceutical medicine, with molecular targets rather than modalities determining potential. Success requires a mechanistic understanding, precision patient selection using pharmacogenomics (CYP2D6, CD36 expression), and modality-specific monitoring. While mRNA-based protein replacement currently faces dosing control challenges that limit its suitability for chronic diseases, advances in self-amplifying mRNA and modRNA with controllable expression kinetics may address these limitations. The future landscape will feature complementary modality use optimized for clinical scenarios, with AI-driven discovery and personalized selection potentially improving response rates from 30% to 60% to over 80%. Global access requires technology transfer, regulatory harmonization, and value-based pricing to bridge the gap between manufacturing cost advantages and realized patient benefits.
AREAS COVERED: We evaluate six primary alternative modalities across FDA- and EMA-approved agents and pipeline candidates (2014-2025): oral small molecules targeting intracellular pathways, RNA therapeutics using gene silencing, CD36-mediated protein degraders (PROTACs), pharmacological chaperones, substrate-reduction therapies, and oral peptide formulations []. Clinical evidence from multiple FDA approvals demonstrates successful substitution: fitusiran achieves an 84-91% reduction in bleeding, iptacopan provides 61% transfusion independence, and deucravacitinib achieves 58.7% PASI-75 response. We identify four mechanistic principles-pathway convergence targeting, functional mimicry, allosteric modulation, and tissue-selective approaches-that can guide recombinant drug substitutions. Manufacturing analysis reveals potential for substantial cost advantages, although actual patient access requires policy intervention beyond market forces.
EXPERT OPINION: Therapeutic alternatives represent a fundamental evolution in pharmaceutical medicine, with molecular targets rather than modalities determining potential. Success requires a mechanistic understanding, precision patient selection using pharmacogenomics (CYP2D6, CD36 expression), and modality-specific monitoring. While mRNA-based protein replacement currently faces dosing control challenges that limit its suitability for chronic diseases, advances in self-amplifying mRNA and modRNA with controllable expression kinetics may address these limitations. The future landscape will feature complementary modality use optimized for clinical scenarios, with AI-driven discovery and personalized selection potentially improving response rates from 30% to 60% to over 80%. Global access requires technology transfer, regulatory harmonization, and value-based pricing to bridge the gap between manufacturing cost advantages and realized patient benefits.